Former Novartis chief Joseph Jimenez discusses breakthroughs in gene therapy, future of CRISPR in medicine

Jimenez
This article or excerpt is included in the GLP’s daily curated selection of ideologically diverse news, opinion and analysis of biotechnology innovation.

Editor’s Note: Novartis CEO Joseph Jimenez retired in January after eight years in the top job at one of the world’s top pharmaceutical companies. During his tenure, the company helped lead a movement that put gene therapies on the map. Scientific American recently interviewed Jimenez.

Scientific American spoke with Jimenez about CAR-T therapy, his hopes for new game-changing treatments that could target disease-causing proteins and problems with the U.S. health care system.

What made you pursue CAR-T, even as other large pharmaceutical companies decided not to bet on the technology?

Novartis was known for breakthrough innovations in oncology back in the early 2000s. We developed Gleevec [which treats certain types of blood and intestinal cancers with less collateral damage to healthy cells than a typical chemotherapy]. When we saw the data on CTL019 CAR-T coming out of Penn—the really early data about five years ago—we decided that this was a place where we were going to place a big bet. The data reminded us of the early days of Gleevec, and so we went out on a limb.

Is there another gamble like that in the works now?

There’s a new technology that Jay Bradner, the head of our research organization, is championing: protein degradation [essentially tricking the body into disposing of harmful proteins], which is a new approach to addressing intractable [disease] targets. We’re also investing heavily in gene editing because we do believe there will be therapeutic value coming out of gene editing.

How confident are you that CRISPR will be usable to edit genes in sick people?

So far it’s promising, but I think everybody is in a wait-and-see mode. There will be twists and turns along the path, as there is with any new technology.

Read full, original post: The Pharma Exec behind the First Approved Gene Therapy Is Hunting for His Next Big Break

Outbreak
Outbreak Daily Digest
Biotech Facts & Fallacies
Talking Biotech
Genetics Unzipped
a a b b a f ac a

Video: Death by COVID: The projected grim toll in historical context

The latest statistics, as of July 10, show COVID-19-related deaths in U.S. are just under 1,000 per day nationally, which is ...
mag insects image superjumbo v

Disaster interrupted: Which farming system better preserves insect populations: Organic or conventional?

A three-year run of fragmentary Armageddon-like studies had primed the journalism pumps and settled the media framing about the future ...
dead bee desolate city

Are we facing an ‘Insect Apocalypse’ caused by ‘intensive, industrial’ farming and agricultural chemicals? The media say yes; Science says ‘no’

The media call it the “Insect Apocalypse”. In the past three years, the phrase has become an accepted truth of ...
types of oak trees

Infographic: Power of evolution? How oak trees came to dominate North American forests

Over the course of some 56 million years, oaks, which all belong to the genus Quercus, evolved from a single undifferentiated ...
biotechnology worker x

Can GMOs rescue threatened plants and crops?

Some scientists and ecologists argue that humans are in the midst of an "extinction crisis" — the sixth wave of ...
food globe x

Are GMOs necessary to feed the world?

Experts estimate that agricultural production needs to roughly double in the coming decades. How can that be achieved? ...
eating gmo corn on the cob x

Are GMOs safe?

In 2015, 15 scientists and activists issued a statement, "No Scientific consensus on GMO safety," in the journal Environmental Sciences ...
Screen Shot at PM

Charles Benbrook: Agricultural economist and consultant for the organic industry and anti-biotechnology advocacy groups

Independent scientists rip Benbrook's co-authored commentary in New England Journal calling for reassessment of dangers of all GMO crops and herbicides ...
Screen Shot at PM

ETC Group: ‘Extreme’ biotechnology critic campaigns against synthetic biology and other forms of ‘extreme genetic engineering’

The ETC Group is an international environmental non-governmental organization (NGO) based in Canada whose stated purpose is to monitor "the impact of emerging technologies and ...
Share via
News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.
Send this to a friend